News coverage about Sunesis Pharmaceuticals (NASDAQ:SNSS) has been trending somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sunesis Pharmaceuticals earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.7537287267238 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Sunesis Pharmaceuticals (NASDAQ SNSS) opened at $5.97 on Friday. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of -0.34. The company has a market capitalization of $204.46, a PE ratio of -3.41 and a beta of 1.71. Sunesis Pharmaceuticals has a twelve month low of $1.82 and a twelve month high of $6.24.
A number of equities research analysts have commented on SNSS shares. Oppenheimer started coverage on Sunesis Pharmaceuticals in a report on Thursday, December 14th. They set a “buy” rating and a $7.00 price target on the stock. Wells Fargo & Co cut Sunesis Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $2.70 to $2.00 in a report on Tuesday, December 5th. Cowen reissued a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Thursday, November 2nd. Zacks Investment Research cut Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 9th. Finally, ValuEngine raised Sunesis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, February 7th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $3.75.
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.